Search

everythinglearnresearchcommunity

for

Search:↓

Topical corticosteroid was not more effective than placebo for children's alopecia areata, and atopy did not change treatment results.

A girl with Crohn's disease developed hair loss due to her increased medication, a rare side effect seen in some children.

Hair loss can be treated with medications like minoxidil and finasteride or surgery, but treatment effectiveness varies by alopecia type and accurate diagnosis is important.

Topical corticosteroid treatment showed no significant difference from placebo in treating alopecia areata in children.

No cure exists for alopecia areata, and treatments are personalized.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Hair loss linked to higher heart disease risk in both men and women.

New treatments for Alopecia Areata show promise but need to be more effective and affordable.

Trichoscopy is a useful, non-invasive way to diagnose different types of hair loss.

The document concludes that accurate diagnosis of different types of hair loss requires careful examination of hair and scalp tissue, considering both clinical and microscopic features.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

The document concludes that proper diagnosis and FDA-approved treatments for different types of hair loss exist, but treatments for severe cases often fail and future improvements may focus on hair follicle stem cells.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Baricitinib is effective and safe for treating severe alopecia areata.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

The document concludes that early recognition and treatment of primary cicatricial alopecia is crucial to prevent permanent hair loss.

People with alopecia areata often have lower levels of vitamin D, zinc, and folate, but more research is needed to understand if supplements can help treat it.

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

Zinc supplements may be needed to treat hair loss in hypothyroidism.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.